Novel Compounds and Drugs and Recent Patents in Treating Multidrug- Resistant and Extensively Drug-Resistant Tuberculosis

Author(s): Attapon Cheepsattayakorn, Ruangrong Cheepsattayakorn

Journal Name: Recent Patents on Anti-Infective Drug Discovery

Volume 7 , Issue 2 , 2012

Become EABM
Become Reviewer


A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.

Keywords: Multidrug, extensively-drug, resistant, tuberculosis, compounds, novel, patents

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [141 - 156]
Pages: 16
DOI: 10.2174/157489112801619683
Price: $58

Article Metrics

PDF: 26